JNPMEDI and KIMCo Sign MOU for the Development of Global Drug R&D Platform

JNPMEDI and KIMCo Sign MOU for the Development of Global Drug R&D Platform

JNPMEDI, a medical data platform company, announced on the 2nd that it has signed a Memorandum of Understanding (MOU) with the Foundation of Korean Innovative Medicine Consortium, known as KIMCo, led by CEO Kyung-Hwa Heo, to collaborate on developing a global new drug R&D platform for the domestic bio-pharmaceutical industry.

At the MOU signing ceremony held on the 1st at the Korea Pharmaceutical and Bio-Pharma Association (KPBMA), key figures including Kwunho Jeong (CEO of JNPMEDI), Yeon-Hong Roh (Chairman of KPBMA), and Kyung-Hwa Heo (CEO of KIMCo) were present.

Through this MOU, both parties will cooperate on ▲establishing a Virtual Data Room (VDR) for licensing agreements and mergers & acquisitions (M&A), ▲conducting valuations (technology value assessment), and ▲building a network connection and investment attraction system. To achieve this, JNPMEDI will contribute its expertise in clinical trials and new drug development consulting, along with its IT capabilities. Meanwhile KIMCo will actively utilize its successful investment and licensing in and out know-how, as well as the pharmaceutical and bio-network of its board members.

The Virtual Data Room (VDR) to be built by JNPMEDI through this MOU is a platform that securely shares and manages highly confidential information, playing a crucial role in licensing in and out, mergers, and M&A between companies. Particularly in the biopharmaceutical industry, it is expected to be used as a key tool for efficient collaboration by securely sharing data, research results, and clinical trial information required for new drug development, thus accelerating development speed. Furthermore, it is anticipated to assist in global market entry for pharmaceutical and bio companies by providing comprehensive consulting required for pharmaceutical technology exports and licensing in and out.

Jeong stated, “In the pharmaceutical and bio-industry, licensing agreements play a role in complementing the drawbacks of long-term substantial investment and lengthy investment recovery periods in new drug development. For domestic bio-ventures, technology transfer at the stage where the pipeline’s value stands out allows them to secure revenue models and focus on subsequent R&D.” He added, “Through the platform developed jointly with KIMCo, JNPMEDI will actively support domestic and international licensing in and out and partnership acquisition for biopharmaceutical companies.”

Heo commented, “Due Diligence in various forms such as new investment, licensing, and M&A is essential in the biopharmaceutical industry’s new drug development process, making the establishment of a Virtual Data Room (VDR) and technology value assessment crucial steps. Through this agreement, KIMCo will build an efficient and innovative collaboration platform for global new drug development to enhance the competitiveness of the domestic biopharmaceutical industry.”